Boston Scientific (NYSE:BSX) has demonstrated significant growth, with shareholders earning a 13% Compound Annual Growth Rate (CAGR) over the last five years. The company has beat out competitors, despite occasional underperformances, and has announced strong Q2 and Q4 2023 results. The second quarter of 2024 also looks promising, with the rally expected to continue. Notably, Boston Scientific's profits experienced nearly a 2x rise, with stock performance and value drawing attention from various investment advisors and researchers. The company has also shown its dedication to innovation, with the initiation of its NAVIGATE-PF study and the strengthening of partnerships, notably with Scivita Medical. Furthermore, Boston Scientific continues to make significant acquisitions, such as Axonics, Silk Road Medical, and Relievant Medsystems. The company's stock recently reached a new 1-year high at $78.37 as growth from cardiovascular devices skyrockets, lifting the 2024 profit forecast.
Boston Scientific Corp BSX News Analytics from Tue, 19 Sep 2023 07:00:00 GMT to Sun, 21 Jul 2024 17:19:24 GMT -
Rating 7
- Information 8
- Rumor 5
